Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
Participants
Bacterial Disease Carrier|Cystic Fibrosis - 18 Years to 99 Years (Adult, Older Adult)
Interventions
Other: Placebo|Biological: WRAIR_PAM-CF1
Outcome measures
Change from baseline in log10 P. aeruginosa total colony counts in quantitative sputum cultures|Desirability of Outcome Ranking (DOOR)|Number of grade 2 or higher treatment-emergent Adverse Events
Related topics
Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis
Antibiotic treatment of early pseudomonas aeruginosa
Antibiotics for pulmonary exacerbations
Inhaled antibiotics in cystic fibrosis
Prophylactic use of oral antistaphylococcal antibiotic
Scheduled antibiotics every 3-4 months / symptom-based treatment